Cognition Therapeutics, Inc. (CGTX) Earnings Call Transcripts

Cognition Therapeutics, Inc.'s Latest Earnings Call - Q4 FY2025

In Q4 and FY 2025, Cognition Therapeutics focused on the development of zervimesine (CT1812) for neurodegenerative diseases, particularly Dementia with Lewy Bodies (DLB) psychosis. The company reported a net loss of $23.5 million, or $0.32 per share, compared to a $34 million loss in 2024. Cash reserves are projected to sustain operations until Q2 2027. Management emphasized the promising Phase II SHIMMER study results, showing an 86% slowing of DLB symptom progression. No revenue was reported, and no changes in guidance were provided.

Reported metrics

Guidance from management

Management did not provide specific revenue or earnings guidance but indicated that cash reserves are sufficient to fund operations through Q2 2027. They emphasized the strategic focus on DLB psychosis and the upcoming FDA meeting.

What management said

Yes. Thank you for the question. As we mentioned, our intent is to develop this now for label relating to psychosis in DLB like we saw, as was mentioned, with NUPLAZID and REXULTI in Alzheimer's disease and Parkinson's disease, dementia. Now we have not completed the FDA meetings yet to comment on exactly what the outcome measure will be. We have to work on that. But you can imagine they'll be very similar to what we...

Yes. Thank you. So we haven't really announced exactly where the trial will be. Certainly, once we have agreement with FDA as we've done with AD, we'll want to seek alignment with EMA before launching trials there. But it's a little premature to talk about exactly what those plans are.

What analysts pressed on

Analysts expressed interest in the regulatory path and trial design for DLB psychosis, questioning whether the next trial would be Phase IIb or Phase III. There were also inquiries about potential synergies with existing CNS medications and the impact of zervimesine on Alzheimer's disease behavioral domains.

Main topics on the call

• DLB Psychosis Development — Cognition Therapeutics is prioritizing the development of zervimesine for DLB psychosis, citing an 86% slowing of progression in neuropsychiatric symptoms as per the NPI 12 index. Management highlighted FDA's interest in...
• Alzheimer's Disease Trials — The company completed enrollment for the START trial in early Alzheimer's disease with 545 participants. Results are expected in 2027. Previous Phase II SHINE study showed a 38% reduction in cognitive decline, with a 95%...
• Financial Position — Cognition reported $37 million in cash and equivalents, with additional grant funds of $35.7 million. This financial position is expected to support operations through Q2 2027. R&D expenses decreased to $37.2 million, re...
• Regulatory Pathway — The company is preparing for discussions with the FDA's Division of Psychiatry to finalize the registrational plan for DLB psychosis. A meeting request has been filed, aiming to align on trial design and endpoints.

Read the full Cognition Therapeutics, Inc. transcript (Q4 FY2025) → Summary generated from the call transcript; every figure above is stated by management on the record.

Earnings Call History

EarningsCalls.dev has 11 Cognition Therapeutics, Inc. earnings call transcripts on record, spanning June 9, 2022 to March 26, 2026. Based on this history, Cognition Therapeutics, Inc. reports semi-annually. The most recent call on file is dated March 26, 2026. The full list is below — each row opens the complete, free-to-read transcript.

Ticker

CGTX

Exchange

NasdaqCM

Country

US

Sector

Health Care

Industry

Pharmaceuticals

Calls on record

11

First call

June 9, 2022

Most recent

March 26, 2026

Reporting cadence

semi-annually